ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

ClinicalTrials.gov ID: NCT04713553

Public ClinicalTrials.gov record NCT04713553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE

Study identification

NCT ID
NCT04713553
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
BioNTech SE
Industry
Enrollment
1,574 participants

Conditions and interventions

Interventions

  • BNT162b2 Biological
  • BNT162b2.B.1.351 Biological

Biological

Eligibility (public fields only)

Age range
12 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 14, 2021
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Last update posted
Dec 21, 2022

2021

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Kaiser Permanente Oakland Oakland California 94611
Clinical Research Consulting Milford Connecticut 06460
Indago Research & Health Center, Inc Hialeah Florida 33012
Research Centers of America Hollywood Florida 33024
Clinical Neuroscience Solutions Orlando Florida 32801
Clinical Research Atlanta Stockbridge Georgia 30281
East-West Medical Research Institute Honolulu Hawaii 96814
Solaris Clinical Research Meridian Idaho 83646
Kentucky Pediatric/Adult Research Bardstown Kentucky 40004
Amici Clinical Research LLC Raritan New Jersey 08869
Accellacare - Wilmington Wilmington North Carolina 28401
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45206
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229-3039
Texas Center for Drug Development, Inc. Houston Texas 77081
Clinical Trials of Texas, LLC San Antonio Texas 78229
Martin Diagnostic Clinic Tomball Texas 77375
J. Lewis Research, Inc. / Foothill Family Clinic South Salt Lake City Utah 84121

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04713553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 21, 2022 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04713553 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →